

Farmaceutica REMEDIA S.A.

STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)

|   | 31.12.2021         | 31.12.2020         |
|---|--------------------|--------------------|
| <b>Net turnover</b>   | <b>477.102.652</b> | <b>441.478.105</b> |
| Income from the sale of goods                               | 474.530.058        | 439.903.203        |
| Commercial discounts granted                                | -1.703.397         | -1.098.781         |
| Income from services provided and rents                     | 4.275.991          | 2.673.683          |
| <b>Other operating income</b>                               | <b>847.324</b>     | <b>41.325.403</b>  |
| <b>OPERATING INCOME - TOTAL</b>                             | <b>477.949.976</b> | <b>482.803.508</b> |
| <b>Expenses with materials</b>                              | <b>439.090.190</b> | <b>394.820.160</b> |
| Expenses regarding goods                                    | 444.975.920        | 399.816.634        |
| Commercial discounts received                               | -8.738.510         | -8.872.597         |
| Expenses with raw materials and consumables                 | 1.974.561          | 2.585.406          |
| Other expenses with materials (inventory objects)           | 98.937             | 195.392            |
| Energy and water expenses                                   | 779.281            | 1.095.323          |
| <b>Expenses with personnel</b>                              | <b>19.465.138</b>  | <b>27.575.662</b>  |
| Salaries and allowances                                     | 17.271.209         | 24.616.138         |
| Expenses with insurance and social protection               | 795.612            | 1.151.057          |
| Other personnel expenses                                    | 1.398.317          | 1.808.468          |
| <b>Amortisations and provisions</b>                         | <b>1.791.200</b>   | <b>2.645.174</b>   |
| Amortisations   | 1.198.795          | 1.103.087          |
| Net provisions  | 423.647            | 408.691            |
| Losses from receivables                                     | 168.758            | 1.133.396          |
| <b>Other operating expenses</b>                             | <b>8.813.429</b>   | <b>14.899.929</b>  |
| Expenses on external services                               | 7.478.877          | 8.659.416          |
| Expenses with other taxes, charges and assimilated payments | 990.377            | 771.985            |
| Other expenses  | 344.175            | 5.468.528          |
| <b>OPERATING EXPENSES - TOTAL</b>                           | <b>469.159.957</b> | <b>439.940.926</b> |
| <b>OPERATING RESULT</b>                                     | <b>8.790.019</b>   | <b>42.862.583</b>  |
| <b>Financial income</b>                                     | <b>220.698</b>     | <b>312.150</b>     |
| Interest income   | 22.071             | 18.494             |
| Income from exchange rate differences                       | 13.220             | 55.588             |
| Income from dividends                                       | 140.333            | 66.733             |
| Advance payment discounts                                   | 45.074             | 171.335            |
| Other financial income                                      | 0                  | 0                  |
| <b>Financial expenses</b>                                   | <b>377.581</b>     | <b>406.117</b>     |
| Expenses regarding interests                                | 0                  | 102.776            |
| Operational leasing interests (IFRS16)                      | 109.560            | 68.916             |
| Expenses due to exchange rate differences                   | 74.186             | 79.464             |
| Discounts received in advance                               | 193.836            | 154.960            |
| Other financial expenses                                    | 0                  |                    |
| <b>FINANCIAL RESULT</b>                                     | <b>-156.883</b>    | <b>-93.967</b>     |
| <b>TOTAL INCOME</b>   | <b>478.170.674</b> | <b>483.115.658</b> |
| <b>TOTAL EXPENSES</b>                                       | <b>469.537.538</b> | <b>440.347.042</b> |

|   |                  |                   |
|---|------------------|-------------------|
| <b>GROSS RESULT</b>   | <b>8.633.136</b> | <b>42.768.616</b> |
| Profit tax  | 1.399.978        | 4.997.042         |
| <b>TOTAL NET PROFIT of which distributable</b>                                    | <b>7.233.158</b> | <b>37.771.574</b> |
| Shareholders of the company   | <b>7.233.158</b> | <b>37.771.574</b> |
| Minority interest   |                  |                   |
|   |                  |                   |
| <b>Other elements of comprehensive income</b>                                     |                  |                   |
| Revaluation of tangible assets  |                  |                   |
| Tax related to other elements of comprehensive income                             |                  |                   |
| Minority interest   |                  |                   |
| <b>COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which attributable:</b> | <b>7.233.158</b> | <b>37.771.574</b> |
| Shareholders of the company   | <b>7.233.158</b> | <b>37.771.574</b> |
| Minority interest   |                  |                   |
|   |                  |                   |
| Earnings per share (in Lei)   |                  |                   |
| - basic   | 0,0758           | 0,3560            |
| - diluted   | 0,0758           | 0,3560            |

\* retreated according to IFRS 16

Chairman of the Board of Administrators  
 "TARUS" - Valentin Norbert TARUS e.U.  
 by representative  
 Valentin – Norbert TARUS

Farmaceutica REMEDIA S.A.

STATEMENT OF FINANCIAL POSITION - consolidated (Lei)

|  | 31.12.2021         | 31.12.2020         |
|--|--------------------|--------------------|
| <b>ASSETS</b>                                      |                    |                    |
| <b>Fixed assets</b>                                | <b>42.655.089</b>  | <b>40.256.854</b>  |
| Tangible assets                                    | 21.313.782         | 28.316.243         |
| Real estate investments                            | 18.657.330         | 8.204.038          |
| Operational leasing assets                         | 1.492.264          | 1.089.773          |
| Software licences                                  | 78.768             | 124.790            |
| Pharmacy licences                                  | 689.200            | 213.636            |
| Participations held in group companies             | 292.320            | 289.520            |
| Participations held in companies outside the group | 5.316              | 5.316              |
| Deposits and guarantees paid                       | 126.110            | 2.013.538          |
|  |                    |                    |
| <b>Current assets</b>                              | <b>206.230.929</b> | <b>202.969.618</b> |
| Stocks   | 40.600.994         | 35.077.188         |
| Trade receivables                                  | 137.629.452        | 130.201.748        |
| Other receivables                                  | 3.782.734          | 3.340.268          |
| Cash and cash equivalents                          | 24.217.749         | 34.350.414         |
|  |                    |                    |
| <b>Accrued expenses</b>                            | <b>2.186.689</b>   | <b>1.236.574</b>   |
|  |                    |                    |
| <b>TOTAL ASSETS</b>                                | <b>251.072.707</b> | <b>244.463.046</b> |
|  |                    |                    |
| <b>EQUITIES AND DEBTS</b>                          |                    |                    |
| <b>Equities</b>                                    | <b>68.223.569</b>  | <b>79.830.650</b>  |
| Share capital                                      | 9.860.311          | 10.921.209         |
| Share premiums                                     | 757.485            | 757.485            |
| Reserves   | 44.055.097         | 34.803.056         |
| Current result                                     | 7.233.158          | 37.771.574         |
| Retained earnings                                  | 6.742.375          | -3.632.398         |
| Retained earnings - retreatment                    | -312.229           | -312.229           |
| Profit distribution                                | 0                  | -365.419           |
| Own shares   | -112.628           | -112.628           |
|  |                    |                    |
| <b>Long-term debts</b>                             | <b>2.544.268</b>   | <b>2.246.739</b>   |
| Debts from financial leasing                       |                    |                    |
| Debts from operational leasing                     |                    |                    |
| Provisions   |                    |                    |
| Debts with deferred income tax                     | 2.544.268          | 2.246.739          |
|  |                    |                    |
| <b>Current debts</b>                               |                    |                    |
| Bank loans   | <b>180.304.871</b> | <b>162.385.658</b> |
| Debts from financial leasing                       |                    |                    |
| Debts from operational leasing                     | 1.339.435          | 867.718            |
| Suppliers and other similar debts                  | 176.037.147        | 159.154.783        |
| Provisions   | 217.307            |                    |
| Current tax debts                                  | -50.770            | 124.581            |
| Other short-term debts                             | 2.761.752          | 2.238.576          |

|                                 |                    |                    |
|---------------------------------|--------------------|--------------------|
|                                 |                    |                    |
| <b>Total debts</b>              | <b>182.849.139</b> | <b>164.632.396</b> |
|                                 |                    |                    |
| <b>TOTAL EQUITIES AND DEBTS</b> | <b>251.072.708</b> | <b>244.463.046</b> |

\* retreated according to IFRS 16

Chairman of the Board of Administrators  
 "TARUS" - Valentin Norbert TARUS e.U.  
 by representative  
 Valentin – Norbert TARUS